MARK2 and chronic myelogenous leukemia, BCR-ABL1 positive: The BCR gene in 22q11.23 acts as a GTPase-activating protein that encodes a novel serine/threonine kinase activity, and can be considered as a candidate tumor suppressor gene involved in meningioma pathogenesis and chronic myeloid leukemia [76,81].